PREVENIR 5 - Persistence of combination of evidence-based medical therapies in patients with recent history of ACS in primary care setting

Head: Amelineau Élisabeth, Bristol-Myers Squibb Schmidely Nathalie, Bristol-Myers Squibb

Last update : 09/05/2017 Version : 2 ID : 139		
General		
Identification		
Detailed name	Persistence of combination of evidence-based medical therapies in patients with recent history of ACS in primary care setting	
Sign or acronym	PREVENIR 5	
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL N° 833542 version 12	
General Aspects		
Medical area	Cardiology	
Keywords	Secondary prevention, care, persistence	
Scientific investigator(s) (Contact)		
Name of the director	Amelineau	
Surname	Élisabeth	
Address	3, rue J. Monier - 92500 Rueil Malmaison	
Phone	+33 (0)1 58 83 60 00	
Email	elisabeth.amelineau@bms.com	
Unit	Bristol-Myers Squibb	
Name of the director	Schmidely	
Surname	Nathalie	
Address	3, rue J. Monier - 92500 Rueil Malmaison	

Phone	+33 (0)1 58 83 60 00
Email	nathalie.schmidely@bms.com
Unit	Bristol-Myers Squibb
Collaborations	
Funding	
Funding status	Private
Details	Bristol-Myers Squibb France
Governance of the database	
Sponsor(s) or organisation(s) responsible	Bristol-Myers Squibb France (BMS)
Organisation status	Private
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	random sampling in clusters
Database objective	
Main objective	Describe the persistence of secondary prevention therapeutics, between 3 and 30 months after hospitalization for a first acute coronary syndrome (ACS), in patients monitored by general practitioners
Inclusion criteria	Patient >=18 years, outpatient seen in a general

	5 1 1 1 0 0
	for a 1st ACS
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	Metropolitan France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2006
Date of last collection (YYYY or MM/YYYY)	2007
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	5111
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Biological data
Clinical data (detail)	Direct physical measures
Biological data (detail)	Total cholesterol, LDL chol, HDL chol, Triglycerides, fasting glucose
Presence of a biobank	No
Health parameters studied	Health care consumption and services

Care consumption (detail)	Medicines consumption
Procedures	
Data collection method	Paper CRF
Participant monitoring	No
Links to administrative sources	No
Promotion and access	
Promotion	
Link to the document	http://www.ncbi.nlm.nih.gov/pubmed/? term=PREVENIR+AND+Amelineau+E[Author]
Access	
Terms of data access (charter for data provision, format of data, availability delay)	Publications
Access to aggregated data	Access on specific project only

Access on specific project only

Access to individual data